ArticleBMC cardiovascular disorders2026
Adipokine-mediated metabolic responses across BMI in acute myocardial infarction.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdipose tissue secretes adipokines, bioactive proteins that regulate inflammation and cardiometabolic processes. During acute myocardial infarction (AMI), adipokine profiles may vary according to body mass index (BMI), yet this association remains underexplored.
aimsTo compare circulating adiponectin, fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), and interleukin-6 (IL-6) between non-obese and obese patients with AMI.
methodsIn this cross-sectional study, 105 patients with AMI were stratified as non-obese (BMI < 25 kg/m², n = 62) or obese (BMI ≥ 25 kg/m², n = 43). Serum adiponectin, GDF15, and IL-6 were measured by Luminex, and FGF21 was measured by ELISA. Clinical variables and lipid indices were compared between BMI groups, and correlation analyses were performed.
resultsAlthough myocardial injury levels were comparable between the two groups, non-obese patients had significantly higher serum levels of adiponectin, FGF21, GDF15, and IL-6 than obese patients (all p < 0.05). In all patients, adiponectin was negatively correlated with total cholesterol, LDL-c, and triglycerides, and positively correlated with HDL-c; however, these associations were not consistently observed within BMI subgroups after stratification and FDR correction. GDF15 and IL-6 also showed inverse correlations with selected lipid parameters in all patients.
conclusionNon-obese AMI patients exhibited higher levels of adiponectin, FGF21, GDF15, and IL-6 compared to obese AMI patients. These adipokine profiles were associated with lipid parameters, notably showing inverse correlations between adiponectin and GDF15 with total cholesterol and LDL-c. These findings highlight the association between adiposity and early metabolic responses in AMI across BMI categories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.